Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...
Overview: Real-time voice interaction is becoming a defining feature of next-generation AI applications. From conversational ...
Vertex is a $90bn market cap Pharma giant with a monopolistic control of the cystic fibrosis industry. CRISPR Therapeutics is an obscure - to some - Swiss Pharma focused on gene therapy, leveraging ...
Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...
Gentleman's Pursuits on MSN
Vertex M36 brings back true field grit
In the world of wristwatches, few designs carry the weight of history like the British field watch from World War II. These ...
BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics today announced that the two companies have entered into a strategic research ...
Technically, Mark Sleeper doesn't know for sure he didn't get the placebo, but nothing in his 27 years of fighting the deadly lung disease cystic fibrosis has made him feel as good as the pill he ...
BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor) today announced that the two companies have entered into a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback